Sign In
Buy ALNY
$297.69
+5.53 (+1.89%)
At Close: Jun 09, 2026
Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine
09:15am, Thursday, 18'th Sep 2025
Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines Members leverage AI-powered dataset to accelerate pharma R&D
Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
05:01pm, Wednesday, 10'th Sep 2025
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 12:20 PM EDT Company Participants Jeffrey Poulton - CFO & Executive VP Conferenc
Alnylam (ALNY) Surges 6.0%: Is This an Indication of Further Gains?
07:46am, Wednesday, 10'th Sep 2025
Alnylam (ALNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes
11:16pm, Tuesday, 09'th Sep 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the pricing of its previously announced private
Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes
04:15pm, Monday, 08'th Sep 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has commenced a private offering of $500
Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth?
11:16am, Monday, 08'th Sep 2025
Alnylam's strong drug sales and advancing partnerships with Regeneron and Roche highlight key growth drivers in the quarters ahead.
Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Citi's Biopharma Back To School Conference Prepared Remarks Transcript
04:58pm, Wednesday, 03'rd Sep 2025
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Citi's Biopharma Back to School Conference September 3, 2025 1:45 PM EDT Company Participants Jeffrey Poulton - CFO & Executive VP Kevin Fitzgerald - Execu
Alnylam Pharmaceuticals: Amvuttra's Launch And Ongoing Clinical Progress Are Positives
12:56am, Wednesday, 03'rd Sep 2025
Alnylam's strong clinical productivity and commercial execution continue to support my view that it's one of the best all-around biotechs, with a robust revenue and earnings outlook. Amvuttra's TTR-CM
ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win
11:51am, Monday, 01'st Sep 2025
Alnylam and Roche report positive phase II KARDIA-3 results for zilebesiran in high-risk hypertension patients, fueling momentum for a phase III study.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUT
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial
10:30am, Saturday, 30'th Aug 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT)
Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension
10:30am, Saturday, 30'th Aug 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam (Nasdaq: ALNY) today announced the decision to initiate a Phase III cardio
Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?
11:11am, Thursday, 28'th Aug 2025
ALNY's Amvuttra revenues surge with 89% sales growth in H1 and a key label expansion, but faces tough competition in the ATTR-CM market.
mRNA Biotechs - Long-Term Value Risks Abound
06:20am, Thursday, 28'th Aug 2025
mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery c
Scenic Enters License and Research Agreement with Alnylam
05:00am, Tuesday, 26'th Aug 2025
Amsterdam, the Netherlands, August 26, 2025 – Scenic Biotech, a pioneer in modifier therapies for severe diseases, today announced a license and research agreement with Alnylam Pharmaceuticals, Inc.
